Point72 Asset Management L.P. acquired a new stake in Cellectis SA (NASDAQ:CLLS) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 70,000 shares of the biotechnology company’s stock, valued at approximately $2,206,000. Point72 Asset Management L.P. owned approximately 0.17% of Cellectis as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently made changes to their positions in the company. Quantbot Technologies LP purchased a new position in Cellectis in the 1st quarter valued at $130,000. Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of Cellectis by 1,300.0% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,600 shares of the biotechnology company’s stock worth $176,000 after acquiring an additional 5,200 shares during the period. Aperio Group LLC purchased a new position in shares of Cellectis during the 1st quarter worth $215,000. Trellus Management Company LLC purchased a new position in shares of Cellectis during the 1st quarter worth $315,000. Finally, UBS Group AG raised its holdings in shares of Cellectis by 143.1% during the 1st quarter. UBS Group AG now owns 15,383 shares of the biotechnology company’s stock worth $485,000 after acquiring an additional 9,054 shares during the period. Institutional investors own 16.76% of the company’s stock.
NASDAQ CLLS opened at $29.68 on Friday. Cellectis SA has a 52 week low of $21.25 and a 52 week high of $38.85. The firm has a market cap of $1.28 billion, a PE ratio of -10.68 and a beta of 1.88.
Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.01). The company had revenue of $8.07 million for the quarter, compared to analysts’ expectations of $9.53 million. Cellectis had a negative return on equity of 37.45% and a negative net margin of 337.45%. research analysts expect that Cellectis SA will post -2.59 earnings per share for the current year.
Several research firms have recently commented on CLLS. Nomura lifted their price target on Cellectis to $73.00 and gave the stock a “buy” rating in a report on Wednesday, March 14th. BidaskClub lowered Cellectis from a “hold” rating to a “sell” rating in a report on Wednesday, May 9th. Oppenheimer lifted their price target on Cellectis from $40.00 to $44.00 and gave the stock an “outperform” rating in a report on Tuesday, June 12th. ValuEngine lowered Cellectis from a “buy” rating to a “hold” rating in a report on Friday, April 27th. Finally, Guggenheim began coverage on Cellectis in a report on Friday, March 16th. They set a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. Cellectis currently has a consensus rating of “Hold” and an average price target of $42.67.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.